Leading science and technology company Merck today announced that Hong Chow will join the Healthcare business sector as Head of China & International, effective October 1. In this role, she will be responsible for the company’s businesses in China, in Japan, in the Europe, Latin America, Asia-Pacific, Middle East, Africa and Russia regions, as well as for the Cardiovascular Diseases, Metabolic Disorders & Endocrinology business unit and the Global Business Innovation team. Chow will report to Peter Guenter, Member of the Executive Committee and CEO Healthcare, and will serve on the Healthcare Executive Committee, the leadership body of the Healthcare business unit. She will perform her new role from her work location in Shanghai, China.
“With her international experience and strong track record in bringing innovative medicines to patients in need of treatment in both developed and emerging markets, particularly in China, Hong Chow will help drive our company’s strategic priorities. I am very much looking forward to working with her on our team and her contribution to achieving our patient and healthcare performance goals.”
- Peter Guenter, Member of the Executive Committee
Chow is a German citizen and currently CEO of Roche Pharmaceuticals in China. She is also a member of the Supervisory Board of Beiersdorf AG. Prior to joining Roche, Chow held various leadership positions at Bayer Healthcare in China as well as Asia Pacific and Europe. She holds a degree in business administration from both the Berlin School of Economics and Law and Anglia Ruskin University in Cambridge, United Kingdom.
“What excites me about Merck is its 353-year tradition of scientific research, entrepreneurial spirit and sustained commitment to human progress,” Chow said. “I am very excited about my new role at Merck and look forward to working with the team to provide vital medicines that make a critical difference for millions of patients every day.”